Abstract
Pulmonary arterial hypertension (PAH) is a devastating complication of systemic lupus erythematosus (SLE). We aim to estimate the putative predictors contributing to early identification of PAH, thus improve appropriate medical intervention and a better prognosis. A retrospective case–control study was conducted. Forty-one SLE patients with PAH and 106 SLE patients without PAH were enrolled. Demographic variables, clinical features, and laboratory data were compared between the two groups. Univariate and multivariate logistic regression models were used to examine the predictors contributing to PAH in SLE. Serositis, Raynaud’s phenomenon, high disease activity, anticardiolipin antibodies, and anti-U1RNP were significantly associated with SLE-PAH. Univariate and multivariate analysis showed that Raynaud’s phenomenon, anticardiolipin antibodies, and anti-U1RNP were independent predictors of PAH in SLE. This study highlighted the clinical pattern of SLE-PAH patients, and underlined the leading predictors of PAH development among patients with SLE. Routine echocardiography is recommended in SLE patients with the independent predictors mentioned above.
Similar content being viewed by others
References
Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G et al (2004) Clinical classification of pulmonary hypertension. J Am Coll Cardiol 43(Suppl S):5S–12S
Tanoue LT (2003) Pulmonary hypertension in the collagen vascular diseases. Semin Respir Crit Care Med 24:287–296
Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V et al (2006) Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 173:1023–1030
Li EK, Tam LS (1999) Pulmonary hypertension in systemic lupus erythematosus: clinical association and survival in 18 patients. J Rheumatol 26:1923–1929
Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM et al (1987) Primary pulmonary hypertension. A national propective study. Ann Intern Med 107(2):216–223
Koh ET, Lee P, Gladman DD, Abu-Shakra M (1996) Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 35:989–993
Quismorio FP Jr, Sharma O, Koss M, Boylen T, Edmiston AW, Thrnton PJ et al (1984) Immunopathologic, clinical studies in pulmonary hypertension associated with systemic lupus erythematosus. Semin Arthritis Rheum 13(4):349–359
Chung L, Liu J, Parsons L, Hassoun PM, McGoon M, Badesch D, et al (2010) Characterization of connective tissue disease associated pulmonary arteraial hypertension from the reveal registry: identifying system sclerosis as a unique phenotype. Chest 138(6):1383–1394
Jais X, Launay D, Yaici A, Le Pavec J, Tcherakian C, Sitbon O et al (2008) Immunosuppressive therapy in lupus-and mixed connective tissue disease-associated pulmonary arterial hypertension. Arthritis Rheum 58(2):521–531
Hochberg MC (1997) For the diagnostic and therapeutic criteria committee of the American college of rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 40:1725
Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM et al (1987) Primary pulmonary hypertension, A national prospective study. Ann Intern Med 107:216–233
Galie N, Torbicki A, Barst R et al (2004) Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The task force on diagnosis and treatment of pulmonary arterial hypertension of the European society of cardiology. Eur Heart J 25(24):2243–2278
Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski H et al (2004) Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 43(Suppl S):40S–47S
Sanchez O, Sitbon O, Jais X, Simonneau G, Humbert M (2006) Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest 130:182–189
Hachulla E, Gresin V, Guillevin L, Carpentier P, Diot E, Sibilia J et al (2005) Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide propective multicenter study. Arthritis Rheum 52(12):3792–3800
Condliffe R, Kiely DG, Peacock AJ, Corris PA, Gibbs JS, Vrapi F et al (2009) Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 179(2):151–157
Chung SM, Lee CK, Lee EY, Yoo B, Lee SD, Moon HB (2006) Clinical aspects of pulmonary hypertension in patients with systemic lupus erythematosus and in patients with idiopathic pulmonary arterial hypertension. Clin Rheumatol 25:866–872
Tanaka E, Harigai M, Tanaka M, Kawaguchi Y, Hara M, Kamatani N (2002) Pulmonary hypertension in systemic lupus erythematosus: evaluation of clinical characteristics and response to immunosuppressive treatment. J Rheumatol 29:282–287
Guillevin L (2009) Vasculopathy and pulmonary arterial hypertension. Rheumatology 48(Suppl 3):iii54–iii57
Wigley FM (1996) Raynaud’s phenomenon and other features of scleroderma, including pulmonary hypertension. Curr Opin Rheumatol 8:561–568
Cefle A, Inanc M, Sayarlioglu M, Kamali S, Gul A, Ocal L, et al (2011) Pulmonary hypertension in systemic lupus erythematosus: relationship with antiphospholipid antibodies and severe disease outcome. Rheumatol Int 31(2):183–189
Kasparian A, Floros A, Gialafos E, Kanakis M, Tassiopoulos S, Kafasi N et al (2007) Raynaud’s phenomenon is correlated with elevated systolic pulmonary arterial pressure in patients with systemic lupus erythematosus. Lupus 16(7):505–508
Levien TL (2010) Advances in the treatment of Raynaud’s phenomenon. Vasc Health Risk Manag 24(6):167–177
Haas C (2004) Pulmonary hypertension associated with systemic lupus erythematosus. Bull Acad Natl Med 188(6):985–997
Assous N, Allanore Y, Batteux F, Meune C, Toulon P, Weill B et al (2005) Prevalence of antiphospholipid antibodies in systemic sclerosis and association with primitive pulmonary arterial hypertension and endothelial injury. Clin Exp Rheumatol 23(2):199–204
Asherson RA, Cervera R (2007) Pulmonary hypertension, antiphospholipid antibodies and syndromes. Clin Rev Allergy Immunol 32(2):153–158
Grunig E, Ehlken N, Ch Nagel (2008) Anticoagulation in pulmonary arterial hypertension. Hamostaseologie 8(4):225–230
Nishimaki T, Aotsuka S, Kondo H, Yamamoto K, Takasaki Y, Sumiya M et al (1999) Immunological analysis of pulmonary hypertension in connective tissue disease. J Rheumatol 26(11):2357–2362
Gussin HA, Ignat GP, Varga J, Teodorescu M (2001) Anti-topoisomerase I (anti-Scl-70) antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 44(2):376–383
McLaughlin VV, Presberg KW, Doyle RL, Abman SH, McCrory DC, Fortin T et al (2004) American College of Chest Physicians. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 126(1 Suppl):78S–92S
Denton CP, Cailes JB, Phillips GD, Wells AU, Black CM, Bois RM (1997) Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. Br J Rheumatol 36:239–243
Vachiery JL, Brimioulle S, Crasset V, Naeije R (1998) False-positive diagnosis of pulmonary hypertension by Doppler echocardiography. Eur Respir J 12:1476–1478
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lian, F., Chen, D., Wang, Y. et al. Clinical features and independent predictors of pulmonary arterial hypertension in systemic lupus erythematosus. Rheumatol Int 32, 1727–1731 (2012). https://doi.org/10.1007/s00296-011-1880-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-011-1880-4